Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can A Safety Study Support A Superiority Claim? Barely, FDA Advisors Say

Executive Summary

FDA advisory committee narrowly endorses CV mortality benefit claim for Boehringer/Lilly's diabetes drug Jardiance, but some panelists question wisdom of relying on study originally designed for cardiovascular safety to support a post-marketing superiority claim.

Advertisement

Related Content

Victoza’s Non-Cardio Safety May Dominate At FDA Panel Review
FDA Conflict Of Interest Waiver On Victoza Is Textbook Example For Supporters, Foes
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
FDA’s Advisory Committees Just Can’t Say “No”
Diabetes Drug Safety Might Be Best Assessed With Real-World Data

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel